Intrommune Therapeutics Appoints Nandini Murthy as Chief Regulatory Officer | Your money

NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a New York-based clinical-stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the arrival of Nandini Murthy as Chief Regulatory Officer.

“Ms. Murthy has proven to be an invaluable asset to Intrommune since joining the organization as a consultant working with our regulatory and clinical development teams,” said Michael Nelson, CEO of Intrommune Therapeutics. Mrs. Murthy’s agreement to join our leadership team as Chief Regulatory Officer demonstrates his commitment to helping food allergy patients live better lives and his expertise in regulatory, clinical and quality affairs is a valuable addition to Intrommune as we move forward with our patient-friendly treatment. peanut allergy, INT301 and our food allergy follow-up products. »

The Company’s Oral Mucosal Immunotherapy (OMIT) platform is based on the well accepted principles of allergic immunotherapy. The company’s initial product, INT301, is an immunotherapy treatment for peanut allergy delivered via a specially formulated toothpaste designed to optimize the exposure of allergenic proteins to a patient’s immune system while cleaning their teeth. Intrommune is currently recruiting patients for its OMEGA INT301 Phase 1 clinical trial.

Ms. Murthy joins Intrommune with significant strategic and operational experience in regulatory affairs, clinical and quality assurance functions. Over the past 25+ years, in full-time or consulting roles, she has led numerous successful submissions to the FDA for new clearances or approvals for combinations and devices. As the founder of a life sciences consulting company, ENEM Consulting LLC, her successful track record in new therapeutics and diagnostics regulatory projects includes drug delivery systems and GRAS pharmaceutical/botanicals .

“I am honored to work on this novel food allergy treatment platform in hopes that these products will help food allergy patients live a better life,” said Nandini Murthy, Chief Regulatory Officer at Intrommune.

About Peanut and Other Food Allergies Food allergies affect more than 220 million people worldwide, including about 32 million people in the United States. food products and therefore difficult to avoid. Many people with peanut allergies are accidentally exposed and experience life-threatening reactions, including anaphylaxis, every year. Unfortunately, food allergy remains an area of ​​enormous unmet medical need.

About Oral Mucosal Immunotherapy™ Oral Mucosal Immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic proteins to immunologically active areas of the oral cavity with the greatest potential for allergy desensitization . The success of allergy immunotherapy relies on constant exposure of a patient’s immune system to gradually “desensitize” the patient to the specific allergy trigger over time. OMIT has advantages over other approaches to allergy immunotherapy due to its targeted delivery and simplified administration, which supports the potential for improved adherence.

About Intrommune Therapeutics intracommunity, dedicated to improving and protecting the lives of food allergy sufferers, is developing the breakthrough Oral Mucosal Immunotherapy (OMIT) treatment platform for food allergies. OMIT is a patient-friendly solution for more than 220 million people worldwide, including 32 million people in the United States, who suffer from life-changing food allergies. Intrommune Therapeutic’s lead product, INT301, has entered Phase 1 clinical trials. All Phase 1 results and future studies are intended to support OMIT as a safe, effective and practical therapy for patients suffering from peanut allergy.

For more information about Intrommune Therapeutics, please visit http://www.intrommune.com

Contact: Stuart Loesch Intrommune Therapeutics (267) 740-2905 [email protected]

Caution Regarding Forward-Looking Statements

This press release may contain “forward-looking statements”. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aims”, “probably will result”, “believes”, “expects”, “will continue”, “anticipates”, “estimates ,” “intend to”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “aim”, “project”, “should”, “will pursue” and similar expressions or variations of these expressions. These forward-looking statements reflect the company’s current expectations regarding its future plans and performance. These forward-looking statements are based on a number of assumptions and estimates which may be inaccurate and are subject to risks. and uncertainties. Actual results could differ materially from those anticipated or expressed in any forward-looking statements made by the company. The company disclaims any obligation or intention to update any forward-looking statements to reflect events or circumstances after the date of you of this press release.

This press release does not contain or constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or any other jurisdiction.

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.